Northern Ireland Cancer Centre, City Hospital, BHSCT
Belfast, Antrim, BT9 7JL, United Kingdom
Location status: Recruiting
NCT Number: NCT07554677
The goal of this clinical trial is to understand the feasibility of a co-designed, pre-radiotherapy exercise programme for people with stage I-III non-small cell lung cancer. This involves people with lung cancer engaging in 20 minutes exercises sessions performed within the radiotherapy department and immediately before each treatment at a personalised intensity.
The main questions it aims to answer are:
To understand the acceptability of the exercise programme through monitoring recruitment rates, attendance of the exercise sessions, and adherence to prescribed exercise intensities. Adverse events will also be monitored to understand programme safety.
Follow-up qualitative interviews will be conducted with participants, their family members, and health care professionals (HCP) to further explore the acceptability of the exercise programme.
In total, participants will be invited to perform up to twenty, supervised exercise sessions scheduled immediately before each treatment within the radiotherapy department. Each exercise session will be twenty minutes in duration and will be performed on a stationary exercise bike. Regarding exercise intensity, there are four levels which may be prescribed depending on people's exercise history, baseline exercise experience, and personal preference. Participants may progress or regress exercise intensity levels throughout the programme depending on their adherence and preference.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Belfast, Antrim, BT9 7JL, United Kingdom
Location status: Recruiting
This is a sequential, mixed method feasibility study consisting of two phases:
Phase 1: Quantitative data collection (feasibility outcomes)
Phase 2: Qualitative data collection (semi-structured interviews)
The exercise programme used in this study was co-designed through a series of workshops and meetings involving individuals affected by lung cancer and healthcare professionals.
Eligible participants must be receiving a prescribed radiotherapy dose of either 55 Gy delivered in twenty fractions or 66Gy administered in 15 fractions, adminstered daily over a 3-4 week period. Accordingly, participants will be prescribed either 15 or 20 exercise sessions, performed once daily and scheduled in alignment with their radiotherapy treatment.
Exercise intensity is personalised and based on a submaximal exercise test conducted at the participant's baseline assessment. This test will be used to determine each participant's maximum heart rate, which will then be entered into the Karvonen formula (Karvonen et al., 1957) to calculate percentage heart rate reserve. This calculation will establish individual heart-rate ranges corresponding to light, moderate, and vigorous exercise intensities. Starting exercise intensity level (1-4) will be determined based on a baseline six-minute walking test, clinical frailty score, and participant preference.
The four levels of exercise intensity increase in difficulty, and incorporate various durations of light, moderate, or high intensity exercise, including:
All participants will wear a chest-strap heart-rate monitor during each exercise session to ensure they are exercising at the prescribed intensity. Session adherence will be defined as completion of at least 75% of the prescribed exercise duration (i.e. 15-minutes).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will participate in up to twenty, supervised exercise sessions, performed within the radiotherapy department, immediately before each treatment. Each session has a 20 minute duration at one of four exercise intensity levels based on the participants baseline assessment results, and preferences.
Study participants will have been diagnosed with stage I-III NSCLC and prescribed radiotherapy administered as 55Gy in 20 fractions over 4 weeks or 60Gy in 15 fractions over 3 weeks as their primary treatment as per standard treatment pathways within the trust
Time frame: Screening and enrolment
The percentage of eligible participants identified and approached through participant screening
Time frame: Screening and recruitment
The total number of potential participants who were approached and agreed to participate as a percentage of the total number who were approached
Time frame: Weeks 4-8 (PReFACe exercise programme)
The total number of attended sessions by the total number provided
Time frame: Weeks 4-8 (PReFACe exercise programme)
Monitoring the participants ability to complete the advised duration and intensity of exercise during each session (adherence is accepted if completed 75% of duration without intensity modification)
Time frame: Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
The number of participants available to provide outcomes at the post-intervention assessment as a percentage of the total number recruited.
Time frame: Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)
Assess the tolerability and safety of the intervention, via recording of intervention-associated adverse events (AE). AEs will be graded according to CTCAE v.5 as:
Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
EORTC QLQ-30 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer.
The QLQ-C30 is composed of both multi-item scales and single-item measures, including:
Five functional scales:
Three symptoms' scales:
A Global health Status (QoL)
Six single items:
All scales and single-item measures range in score from 0 to 100. High scale scores represent a higher response level, thus:
Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
EORTC QLQ-LC13 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer.
The QLQ-LC13 incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing:
All single-item measures range in score from 0 to 100 with high scale scores representing a higher response level, thus:
Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
Understanding the impact of the exercise programme on symptom burden on participants experience of pain using a 1-10 likert scale:
Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)
Understanding the impact of the exercise programme on symptom burden on participants experience of fatigue using a 1-10 likert scale:
Time frame: Week 0 (baseline assessment), daily through PReFACe exercise programme (weeks 4-8) and end of study assessment (week 8)
The modified MRC dyspnoea scale is a 5-point (0-4) questionnaire that assesses a patient's breathing difficulty, or dyspnoea, during activity. Higher scores correspond with more breathlessness etc:
Time frame: Weeks 8-14 post-intervention follow-up period
Conduct of post-intervention, semi-structured, qualitative interviews with the following groups:
A total of 15 participants (n=5 from each group) is deemed sufficient to achieve data saturation.
Semi-structured interview schedules were pre-constructed for each group.
Interview schedules consist of open-ended questions to explore the participants/experience of the exercise programme in their own words.
No scales are used as a part of this outcome.
Time frame: Baseline assessment (week 0), weekly throughout the PReFACe exercise programme (weeks 4-8) and at post-study assessment (week 8)
The distress thermometer is a valid, and accurate screening tool used to quickly monitor for patient's distress with advanced cancer.
The thermometer uses a 0-10 scale to measure patient distress over the past week with 0 representing no distress and 10 representing extreme distress.
The thermometer also features a "Problem List" (covering practical, family, emotional, spiritual, and physical issues) to pinpoint causes of distress for referral
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
A well-documented, validated and standardised sub-maximal fitness test measuring the distance a person can walk on a flat, solid surface in six minutes. Participants walk back and forth along a measured track to measure total distance covered in meters within six minutes.
Greater distance covered (meters) indicate greater baseline fitness.
Greater post-test distance covered (meters) than baseline scores indicate improvements in basic mobility.
Reduced post-test distance covered (meters) than baseline scores indicate reductions in basic mobility.
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
A well-documented, validated, and standardised test to measure functional lower extremity strength. Participants perform as many sit-to-stand reps as they can within 30 seconds.
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
The Rockwood CFS is used as a valid assessment tool for screening frailty in older adults. This is a 1-9 scale, with higher scores indicating greater frailty:
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
The IPAQ-SF will be used to explore the influence of the pre-radiotherapy exercise programme on the participant's weekly physical activity levels pre- and post-study. Based on results, physical activity levels based on scores can be calculated as:
Time frame: Baseline assessment (week 0) and post-study assessment (week 8)
The Huffman Exercise Satisfaction Scale was developed with stakeholders as a novel approach to measure older adults (aged ≥55 years) satisfaction with their physical activity levels.
There questionnaire measures two scales:
Mean scores are taken from each scale to total participants exercise enjoyment and satisfaction.
Interested in participating?
Request InfoQueen's University, Belfast
Other
Feasibility of a Co-designed PRe-radiotherapy Exercise Programme for People With Stage I-III Non-small Cell Lung cAnCEr: A Single-centre, Single Arm Pilot Study
Acronym: PReFACe
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07227077
Behavior, Bladder Cancer
Milwaukee, Wisconsin, United States
View Trial DetailsNCT06245343
Behavior, Lung Cancer
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT04871412
Behavior, Digestive System Diseases
Ottawa, Ontario, Canada
View Trial DetailsNCT05349227
Adnexal Diseases, Behavior
Gainesville, Florida, United States
View Trial Details